Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.

doi:10.1038/s41467-024-47771-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.

Nature communications - 23 Apr 2024

Pucci Perla, Lee Liam C, Han Miaojun, Matthews Jamie D, Jahangiri Leila, Schlederer Michaela, Manners Eleanor, Sorby-Adams Annabel, Kaggie Joshua, Trigg Ricky M, Steel Christopher, Hare Lucy, James Emily R, Prokoph Nina, Ducray Stephen P, Merkel Olaf, Rifatbegovic Firkret, Luo Ji, Taschner-Mandl Sabine, Kenner Lukas, Burke G A Amos, Turner Suzanne D

Abstract excerpt

Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitating drug combination therapeutic approaches. Using high-throughput, genome-wide CRISPR-Cas9 knockout screens, we identify miR-1304-5p loss as a desensitizer to ALK TKIs in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Farnesyltranstransferase

Share to GTP Phosphohydrolases

Share to Neuroblastoma

Share to Piperidines

Share to Pyridines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38653965
DOI: 10.1038/s41467-024-47771-x
PMCID: PMC11039739

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.PMID 38653965Read ↗

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.Semantic proximity Read ↗

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.Semantic proximity Read ↗

Functional identification of molecular oncotargets associated with the resistance to ALK inhibition in neuroblastoma via genome-wide CRISPR-Cas9 screensSemantic proximity Read ↗

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degradersSemantic proximity Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatmentSemantic proximity Read ↗

Targeted Therapy for Neuroblastoma: ALK InhibitorsSemantic proximity Read ↗

ALK in Neuroblastoma: Biological and Therapeutic ImplicationsSemantic proximity Read ↗

Disruption of Cooperation Between Ras and MycN in Human Neuroblastoma Cells Promotes Growth ArrestSemantic proximity Read ↗

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Semantic proximity Read ↗

Targeting anaplastic lymphoma kinase in neuroblastomaSemantic proximity Read ↗

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.